TITLE

Drug-resistant pneumococcal pneumonia: clinical relevance and approach to management

AUTHOR(S)
Fuller, J.; McGeer, A.; Low, D.
PUB. DATE
December 2005
SOURCE
European Journal of Clinical Microbiology & Infectious Diseases;Dec2005, Vol. 24 Issue 12, p780
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Community-acquired pneumonia is the most common infectious disease that causes death, with Streptococcus pneumoniae remaining the leading causative pathogen. The worldwide incidence of infections caused by pneumococci resistant to penicillin, macrolides, and other antimicrobial agents has increased at an alarming rate during the past 2 decades. Yet, these agents are still used as first-line empirical therapy in the outpatient setting. There are several reasons for this, including the infrequency of making a pathogen-specific diagnosis, the failure of studies to demonstrate the relevance of resistance, and the infrequency with which clinicians recognize clinical failures. Despite this, there is mounting evidence that supports the practice of using high doses of some antimicrobial agents, a more active antimicrobial agent within a class, or switching to another class of antimicrobial agents when a patient is identified as being at an increased risk of infection with a resistant pneumococcus. There is now information that will allow the physician to identify not only the patient at risk for infection with a resistant pneumococcus but also the antimicrobial class and, in some cases, the agent within the class to which the organism is more likely to be resistant. This will allow clinicians to better define optimal therapy for patients with community-acquired pneumonia.
ACCESSION #
19316318

 

Related Articles

  • The Decline of Pneumococcal Resistance after Cessation of Mass Antibiotic Distributions for Trachoma. Haug, Sara; Lakew, Takele; Habtemariam, Gabremaskal; Alemayehu, Wondu; Cevallos, Vicky; Zhaoxia Zhou; House, Jenafir; Ray, Kathryn; Porco, Travis; Rutar, Tina; Keenan, Jeremy; Lietman, Thomas M.; Gaynor, Bruce D. // Clinical Infectious Diseases;9/1/2010, Vol. 51 Issue 5, p571 

    After 6 biannual mass distributions of oral azithromycin for trachoma in Ethiopian communities, 76.8% (95% confidence interval [CI], 66.3%-85.1%) of nasopharyngeal Streptococcus pneumoniae isolates from children aged 1-5 years were resistant to macrolides. Twelve and 24 months after the last...

  • Clinical Relevance of Macrolide-Resistant Streptococcus pneumoniae for Community-Acquired Pneumonia. Lynch III, Joseph P.; Martinez, Fernando J. // Clinical Infectious Diseases;3/1/2002 Supplement 1, Vol. 34, pS27 

    Discusses the prevalence of macrolide resistance among Streptococcus pneumoniae, risk factors and mechanisms responsible for resistance, therapeutic strategies and implications for the future. Impact of antimicrobial resistance on clinical outcomes; Clinical significance of in vitro macrolide...

  • Evolution and molecular characterization of macrolide-resistant Streptococcus pneumoniae in Canada between 1998 and 2008. Wierzbowski, Aleksandra K.; Karlowsky, James A.; Adam, Heather J.; Nichol, Kim A.; Hoban, Daryl J.; Zhanel, George G. // Journal of Antimicrobial Chemotherapy (JAC);Jan2014, Vol. 69 Issue 1, p59 

    Objectives Studies were performed to assess resistance mechanisms, multidrug resistance (MDR), genetic relatedness, serotype distribution, heptavalent pneumococcal conjugate vaccine (PCV7) coverage and pili virulence factors among macrolide-resistant Streptococcus pneumoniae (MRSP) isolated from...

  • Emergence of Rifampin-Resistant Streptococcus pneumoniae as a Result of Antimicrobial Therapy for Penicillin-Resistant Strains. van Tilburg, Peter M. B.; Bogaert, Debby; Sluijter, Marcel; Jansz, Arjan R.; de Groot, Ronald; Hermans, Peter W. M. // Clinical Infectious Diseases;10/15/2001, Vol. 33 Issue 8, pe93 

    Describes the emergence of primary rifampin resistance in patients with chronic obstructive pulmonary disease in a Dutch hospital during therapeutic management of an outbreak of multidrug-resistant pneumococci. Infections caused by Streptococcus pneumoniae; Antimicrobial agents that can be used...

  • Antimicrobial Use and the Emergence of Antimicrobial Resistance with Streptococcus pneumoniae in the United States. Doem, Gary V. // Clinical Infectious Diseases;9/15/2001 Supplement 3, Vol. 33, pS187 

    The rapid emergence of resistance to antimicrobial agents by Streptococcus pneumoniae in the United States has been influenced by various factors, including the clonal nature of most resistant strains and the fact that organisms with a multiresistant phenotype have become stably endemic. The...

  • Antimicrobial-Drug Use and Changes in Resistance in Streptococcus pneumoniae. Diekema, Daniel J.; Brueggemann, Angela B.; Doern, Gary V. // Emerging Infectious Diseases;Sep/Oct2000, Vol. 6 Issue 5, p552 

    Resistance of Streptococcus pneumoniae to antimicrobial drugs is increasing. To investigate the relationship between antimicrobial use and susceptibility of S. pneurnoniae isolates at 24 U.S. medical centers, we obtained data on outpatient antimicrobial-drug use for the regions surrounding 23 of...

  • ANTIMICROBIAL RESISTANCE IN STREPTOCOCCUS PNEUMONIAE: MECHANISMS AND CURRENT EPIDEMIOLOGY. da Cunha, Gabriela Rosa; Caierão, Juliana; d'Azevedo, Pedro Alves; Gomes Dias, Cícero Armídio // Clinical & Biomedical Research;2014, Vol. 34 Issue 2, p97 

    Infections caused by Streptococcus pneumoniae are a worrisome public health problem worldwide. Young children and the elderly are the main age groups affected and the highest burden of the disease is found in developing countries. Pneumococcal infections cause 11% of the total infant deaths,...

  • Failure of Macrolide Antibiotic Treatment in Patients with Bacteremia Due to Erythromycin-Resistant. Lonks, John R.; Garau, Javier; Gomez, Lucia; Xercavins, Mariona; Ochoa de Echaguen, Anna; Gareen, Ilana F.; Reiss, Philip T.; Madeiros, Antone A. // Clinical Infectious Diseases;9/1/2002, Vol. 35 Issue 5, p556 

    The rate of macrolide resistance among Streptococcus pneumoniae is increasing, but some investigators have questioned its clinical relevance. We conducted a matched case-control study of patients with bacteremic pneumococcal infection at 4 hospitals to determine whether development of...

  • In Vivo Veritas: In Vitro Macrolide Resistance in Systemic Streptococcus pneumoniae Infections Does Result in Clinical Failure. Jacobs, Michael R. // Clinical Infectious Diseases;9/1/2002, Vol. 35 Issue 5, p565 

    Editorial. Comments on a research article by J.R. Lonks et al. which deals with the failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae, published in the volume 35, 2002 edition of the periodical 'Clinical Infectious...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics